[1] | Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005 Nov; 46(5): 799–811. |
[2] | Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004; 65(4): 1492–8. |
[3] | Truong Q a, Ptaszek LM, Charipar EM, Taylor C, Fontes JD, Kriegel M, et al. Performance of electrocardiographic criteria for left ventricular hypertrophy as compared with cardiac computed tomography: from the Rule Out Myocardial Infarction Using Computer Assisted Tomography trial. J Hypertens. 2010; 28(9): 1959–67. |
[4] | Wang AY-M, Lai K-N. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008; 19: 1643–52. |
[5] | Dong D, Yang B. Role of microRNAs in cardiac hypertrophy, myocardial fibrosis and heart failure. Acta Pharm Sin B [Internet]. 2011;1(1):1–7. Available from: http://dx.doi.org/10.1016/j.apsb.2011.04.010. |
[6] | Nair N, Kumar S, Gongora E, Gupta S. Circulating miRNA as novel markers for diastolic dysfunction. Mol Cell Biochem. 2013 Apr; 376(1–2): 33–40. |
[7] | Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article. J Am Coll Cardiol [Internet]. 2003; 42(5): 954–70. Available from: http://www.sciencedirect.com/science/article/pii/S0735109703010659. |
[8] | Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging [Internet]. 2015; 16(3): 233–71. Available from: http://dx.doi.org/10.1016/j.echo.2014.10.003. |
[9] | London G. Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transplant. 2001; 16 Suppl 2:3–6. |
[10] | Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation. 2000 Mar; 101(9): 1002–6. |
[11] | Duran M, Unal A, Inanc MT, Esin F, Yilmaz Y, Ornek E. Effect of maintenance hemodialysis on diastolic left ventricular function in end-stage renal disease. Clinics (Sao Paulo). 2010; 65(10): 979–84. |
[12] | Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May; 63(5): 1934–43. |
[13] | Dou L, Sallee M, Cerini C, Poitevin S, Gondouin B, Jourde-Chiche N, et al. The cardiovascular effect of the uremic solute indole-3 acetic acid. J Am Soc Nephrol. 2015 Apr; 26(4): 876–87. |
[14] | Lin C-J, Wu V, Wu P-C, Wu C-J. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure. PLoS One. 2015; 10(7): e0132589. |
[15] | Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007 May; 13(5): 613–8. |
[16] | Dong D, Chen C, Huo R, Wang N, Li Z, Tu Y, et al. Reciprocal Repression Between MicroRNA-133 and Calcineurin Regulates Cardiac Hypertrophy A Novel Mechanism for Progressive Cardiac Hypertrophy. 2010. |
[17] | Wen P, Song D, Ye H, Wu X, Jiang L, Tang B, et al. Circulating MiR-133a as a biomarker predicts cardiac hypertrophy in chronic hemodialysis patients. PLoS One. 2014; 9(10). |
[18] | van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006 Nov; 103(48): 18255–60. |
[19] | Chen J-F, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006 Feb; 38(2): 228–33. |
[20] | Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkentin JD, Gary-Bobo G, et al. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation. 2005 Nov; 112(19): 2930–9. |
[21] | Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2009 Jan; 104(2): 170–8, 6p following 178. |
[22] | Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, et al. Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney Int. 2002; 62(5): 1884–90. |
[23] | Fredericks S, Chang R, Gregson H, Bewick M, Collinson PO, Gaze D, et al. Circulating cardiac troponin-T in patients before and after renal transplantation. Clin Chim Acta. 2001 Aug; 310(2): 199–203. |
[24] | Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. Heart [Internet]. 2006 May 12;92(6):804 LP-809. Available from: http://heart.bmj.com/content/92/6/804.abstract. |
[25] | Jiang Y, Wang H, Li Y, Guo S, Zhang L, Cai J. Peripheral blood miRNAs as a biomarker for chronic cardiovascular diseases. Sci Rep. 2014; 4: 5026. |